Cargando…

Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Najim, Omar, Papadimitriou, Konstantinos, Broeckx, Glenn, Huizing, Manon, Tjalma, Wiebren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477975/
https://www.ncbi.nlm.nih.gov/pubmed/37675216
http://dx.doi.org/10.3389/fonc.2023.1221773
_version_ 1785101247765807104
author Najim, Omar
Papadimitriou, Konstantinos
Broeckx, Glenn
Huizing, Manon
Tjalma, Wiebren
author_facet Najim, Omar
Papadimitriou, Konstantinos
Broeckx, Glenn
Huizing, Manon
Tjalma, Wiebren
author_sort Najim, Omar
collection PubMed
description Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
format Online
Article
Text
id pubmed-10477975
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104779752023-09-06 Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis Najim, Omar Papadimitriou, Konstantinos Broeckx, Glenn Huizing, Manon Tjalma, Wiebren Front Oncol Oncology Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies. Frontiers Media S.A. 2023-08-22 /pmc/articles/PMC10477975/ /pubmed/37675216 http://dx.doi.org/10.3389/fonc.2023.1221773 Text en Copyright © 2023 Najim, Papadimitriou, Broeckx, Huizing and Tjalma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Najim, Omar
Papadimitriou, Konstantinos
Broeckx, Glenn
Huizing, Manon
Tjalma, Wiebren
Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title_full Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title_fullStr Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title_full_unstemmed Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title_short Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
title_sort validation of liquid biopsy for esr1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477975/
https://www.ncbi.nlm.nih.gov/pubmed/37675216
http://dx.doi.org/10.3389/fonc.2023.1221773
work_keys_str_mv AT najimomar validationofliquidbiopsyforesr1mutationanalysisinhormonesensitivebreastcancerapooledmetaanalysis
AT papadimitrioukonstantinos validationofliquidbiopsyforesr1mutationanalysisinhormonesensitivebreastcancerapooledmetaanalysis
AT broeckxglenn validationofliquidbiopsyforesr1mutationanalysisinhormonesensitivebreastcancerapooledmetaanalysis
AT huizingmanon validationofliquidbiopsyforesr1mutationanalysisinhormonesensitivebreastcancerapooledmetaanalysis
AT tjalmawiebren validationofliquidbiopsyforesr1mutationanalysisinhormonesensitivebreastcancerapooledmetaanalysis